Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.
By S. Bhasin, G. Cunningham, F. Hayes, A. Matsumoto, P. Snyder, R. Swerdloff, Victor M. Montori. Journal of Clinical Endocrinology and Metabolism, 2006
875 citations recorded by the source corpus.
OBJECTIVE The objective was to provide guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men. PARTICIPANTS The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a professional writer. The Task Force received no corporate funding or remuneration. EVIDENCE The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation group. CONSENSUS PROCESS Consensus was guided by systematic reviews of evidence and discussions during three group meetings, several conference calls, and e-mail communications. The drafts prepared by the panelists with the help of a professional writer were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Committee, and Council. The version approved by the Council was placed on The Endocrine Society's web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. CONCLUSIONS We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and in some patients by measurement of free or bioavailable testosterone level, using accurate assays. We recommend testosterone therapy for symptomatic men with androgen deficiency, who have low testosterone levels, to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 3 ng/ml without further urological evaluation, erythrocytosis (hematocrit > 50%), hyperviscosity, untreated obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score (IPSS) greater than 19, or class III or IV heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/a4640647af8527bc1558b4545f70f7820e305df2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Low serum testosterone and mortality in older men. (2008, result): “Repeat sampling of men with an initially low testosterone level is recommended to confirm androgen deficiency (35), but this and other epidemiological studies were based on a single measurement of testosterone.”
- Handbook of Clinical Sexuality for Mental Health Professionals (2004, background): “Androgen deficiency is defined in men as having a low total (<300 ng/dl) and free (<5 ng/dl) testosterone plus the presence of low libido, erectile dysfunction, osteoporosis, or fracture, or two or more of following symptoms: sleep disturbance, depressed mood, lethargy, or diminished physical perfor”
- Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. (2009, background): “Regimens to change secondary sex characteristics follow the general principle of hormone replacement treatment of male hypogonadism (85).”
- Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline (2017, neutral): “Key issues include maintaining testosterone levels in the physiologic normal male range and avoiding adverse events resulting from excess testosterone therapy, particularly erythrocytosis, sleep apnea, hypertension, excessive weight gain, salt retention, lipid changes, and excessive or cystic acne (”
- Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. (2011, background): “If the drug cannot be discontinued or substituted and the patient has hypogonadal symptoms or low bone mass, estrogen or testosterone therapy should be considered (60).”